This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Walgreens (WBA), VillageMD Plan to Expand Into Tampa, Florida
by Zacks Equity Research
Walgreens (WBA), VillageMD to open 20 new Village Medical at Walgreens primary care practices in the Tampa area to improve access to overall care for patients with chronic conditions.
Here's Why You Should Hold on to Teleflex (TFX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Teleflex (TFX) owing to better-than-anticipated results in the third quarter and strength in the Vascular business.
Alcon (ALC) Q3 Earnings Beat Estimates, Margin Improves
by Zacks Equity Research
Alcon (ALC) records year-over-year growth across all sales categories in Surgical and Vision Care in Q3.
Shockwave Medical (SWAV) Gains 0.6% Post Q3 Earnings Beat
by Zacks Equity Research
Shockwave Medical's (SWAV) third-quarter results reflect robust revenue growth and expansion in gross margin.
National Vision (EYE) Q3 Earnings Top Estimates, Margins Fall
by Zacks Equity Research
Strength in America's Best and Eyeglass World brands drove National Vision's (EYE) revenues in the third quarter of 2021.
Haemonetics (HAE) Q2 Earnings Lag Estimates, Gross Margin Grows
by Zacks Equity Research
Haemonetics (HAE) revenues increased year over year in the fiscal second quarter, supported by recovery across major businesses, especially Hospital and the initial Plasma Persona rollouts.
NuVasive (NUVA) Q3 Earnings Miss Estimates, 2021 Guidance Down
by Zacks Equity Research
NuVasive (NUVA) reported lower-than-expected earnings and revenues with COVID-led headwinds and healthcare staffing shortages dampening the Q3 top-line growth.
Cardiovascular Systems (CSII) Q1 Loss Wider Than Expected
by Zacks Equity Research
Cardiovascular Systems' (CSII) coronary franchise registers strong performance globally on continued strength in Japan and Europe.
Inari Medical (NARI) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Inari Medical's (NARI) third-quarter results benefit from new product launches and continued U.S. commercial expansion.
Cardinal Health (CAH) Q1 Earnings Lag, Revenues Top Estimates
by Zacks Equity Research
Although Cardinal Health (CAH) witnessed gross margin contraction in its fiscal first-quarter results, rise in revenues in both its segments is encouraging.
SmileDirectClub (SDC) Q3 Earnings Lag Estimates, Margin Grows
by Zacks Equity Research
SmileDirectClub (SDC) registered a year-over-year decline in revenues in the third quarter due to lower unique aligner shipment.
Nevro (NVRO) Q3 Earnings Miss Estimates, Revenues Surpass
by Zacks Equity Research
Nevro (NVRO) reported wider-than-expected loss during the third quarter with a year-over-year decline in revenues across U.S. and international businesses.
Phirbo (PAHC) Q1 Earnings Lag Estimates, Revenue View Up
by Zacks Equity Research
Phirbo's (PAHC) year-over-year increase in Q1 sales is primarily due to stronger international demand for poultry and cattle products and more robust growth in the nutritional specialties and vaccine product lines.
AMN Healthcare (AMN) Loses 13.1% Despite Q3 Earnings Beat
by Zacks Equity Research
AMN Healthcare's (AMN) robust Q3 results demonstrate its segmental strength.
Glaukos (GKOS) Gains 3.6% Despite Reporting a Loss in Q3
by Zacks Equity Research
Despite reporting third-quarter loss, Glaukos' (GKOS) results reflect a significant rise in revenues.
Integra (IART) Q3 Earnings Top Estimates, 2021 EPS View Up
by Zacks Equity Research
Integra (IART) reports better-than-expected earnings and revenues with robust demand for the company's products driving the top line in third-quarter 2021.
Hill-Rom (HRC) Q4 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Strong underlying performance and continued recovery across all three business segments drove Hill-Rom's (HRC) fourth-quarter fiscal 2021 revenues.
Quidel (QDEL) Q3 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
Quidel (QDEL) records a strong Q3 performance despite lower revenues from two of its product categories.
LHC Group (LHCG) Q3 Earnings Match Estimates, Down Y/Y
by Zacks Equity Research
LHC Group's (LHCG) third-quarter results benefit from organic growth in both home health and hospice admissions.
Inogen (INGN) Earnings and Revenues Surpass Estimates in Q3
by Zacks Equity Research
Inogen's (INGN) third-quarter results benefit from higher revenues across its segments.
Globus Medical (GMED) Q3 Earnings Top Estimates, Revenues Lag
by Zacks Equity Research
Globus Medical (GMED) Q3 results reflect an estimated $12 million to $13 million in correlated revenue headwinds in the United States.
Allscripts' (MDRX) Q3 Earnings Beat Estimates, Margins Up
by Zacks Equity Research
Allscripts' (MDRX) robust Q3 results demonstrate strength in both segments.
Illumina (ILMN) Q3 Earnings Top Estimates, 2021 Revenue View Up
by Zacks Equity Research
Illumina (ILMN) exited the third quarter with better-than-expected results on strength in Core Illumina and the newly-acquired GRAIL businesses.
Insulet (PODD) Q3 Earnings Miss Estimates, Revenues Top
by Zacks Equity Research
Insulet (PODD) reports better-than-expected revenues for third-quarter 2021 on strong performance of Omnipod, both in U.S. and international markets.
Accuray (ARAY) Q1 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Accuray (ARAY) registers growth in both Service and Product revenues during fiscal Q1.